Floatz logo

Immunoglobulin G4-Kappa, Anti-[Homo Sapiens Lgals3 (Galectin 3)], Humanized Monoclonal Antibody (Gamma4 Heavy Chain Humanized (1-442) [Vh (Homo Sapiens Ighv1-3*01 (88.7%) -(Ighd) -Ighj6*01 (93.3%), Cdr-Imgt [8.8.9] (26-33.51-58.97-105)) (1-116)-Homo Sapiens Ighg4*01, Ng4M(A) Ch2 L92, G4V5 H P10 (Ch1 (117-214), Hinge 1-12 S10>P (224)(215-226), Ch2 L92 (305) (227-336), Ch3 (337-441), Chs K2>Del (442)) (117-442)], (130-219')-Disulfide With Kappa Light Chain Humanized (1'-219') [V-Kappa(Homo Sapiens Igkv2D-29*02 (89.0%) -Igkj2*01(100%), Cdr-Imgt [11.3.9] (27-37.55-57.94-102)) (1'-112') -Homo Sapiens Igkc*01 (100%), Km3 A45.1(158), V101 (196) (113'-219')]; Dimer (222-222'':225-225'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Glycoform Alfa)

Alzheimer Disease

Explore 299 assets in Alzheimer Disease →
Floatz Rating
B58/100
Confidence
Indicative
v0.2
Sponsor
TrueBinding, Inc.
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
53High confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT05476783CT.gov
A Long Term Extension Study to Assess the Safety of TB006 in Participants With Alzheimer's Disease
—Terminated———
NCT05074498CT.gov
Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of TB006 in Participants With Alzheimer's Disease
—Completed———
NCT04920786CT.gov
Sequential Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of TB006 in Healthy Subjects
—Completed———
NCT05959239CT.gov
TB006 Expanded Access (EA) Compassionate Use
—Available———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Alzheimer Disease

AssetSponsorPhaseRating
Immunoglobulin G4-Kappa, Anti-[Homo Sapiens Lgals3 (Galectin 3)], Humanized Monoclonal Antibody (Gamma4 Heavy Chain Humanized (1-442) [Vh (Homo Sapiens Ighv1-3*01 (88.7%) -(Ighd) -Ighj6*01 (93.3%), Cdr-Imgt [8.8.9] (26-33.51-58.97-105)) (1-116)-Homo Sapiens Ighg4*01, Ng4M(A) Ch2 L92, G4V5 H P10 (Ch1 (117-214), Hinge 1-12 S10>P (224)(215-226), Ch2 L92 (305) (227-336), Ch3 (337-441), Chs K2>Del (442)) (117-442)], (130-219')-Disulfide With Kappa Light Chain Humanized (1'-219') [V-Kappa(Homo Sapiens Igkv2D-29*02 (89.0%) -Igkj2*01(100%), Cdr-Imgt [11.3.9] (27-37.55-57.94-102)) (1'-112') -Homo Sapiens Igkc*01 (100%), Km3 A45.1(158), V101 (196) (113'-219')]; Dimer (222-222'':225-225'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Glycoform Alfa) (this asset)TrueBinding, Inc.P2B · 58
4-((1E)-2-(6-(2-)2-(2-FLUOROETHOXY)ETHOXY)ETHOXY)PYRIDIN-3-YL)ETHENYL)-N-METHYLBENZENAMINEAkiva MintzP4BBB
MemantineCarnot LaboratoriesP4BBB
EscitalopramNYU Langone HealthP4BBB
FlortaucipirEli RadiopharmaP4BBB
RivastigmineAnhui Provincial HospitalP4BBB
FlorbetabenNational Institute of Mental Health (NIMH)P4BBB
6H-BENZOFURO(3A,3,2-EF)(2)BENZAZEPIN-6-OL, 4A,5,9,10,11,12-HEXAHYDRO-3-METHOXY-11-METHYL-, (4AS,6R,8AS)Anhui Provincial HospitalP4BBB
SertralineAstraZenecaP4BBB

+42 more in the Alzheimer Disease cohort

Other indications for Immunoglobulin G4-Kappa, Anti-[Homo Sapiens Lgals3 (Galectin 3)], Humanized Monoclonal Antibody (Gamma4 Heavy Chain Humanized (1-442) [Vh (Homo Sapiens Ighv1-3*01 (88.7%) -(Ighd) -Ighj6*01 (93.3%), Cdr-Imgt [8.8.9] (26-33.51-58.97-105)) (1-116)-Homo Sapiens Ighg4*01, Ng4M(A) Ch2 L92, G4V5 H P10 (Ch1 (117-214), Hinge 1-12 S10>P (224)(215-226), Ch2 L92 (305) (227-336), Ch3 (337-441), Chs K2>Del (442)) (117-442)], (130-219')-Disulfide With Kappa Light Chain Humanized (1'-219') [V-Kappa(Homo Sapiens Igkv2D-29*02 (89.0%) -Igkj2*01(100%), Cdr-Imgt [11.3.9] (27-37.55-57.94-102)) (1'-112') -Homo Sapiens Igkc*01 (100%), Km3 A45.1(158), V101 (196) (113'-219')]; Dimer (222-222'':225-225'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Glycoform Alfa)

IndicationSponsorPhaseRating
Parkinson Disease—P2CCC · 53
Ischemic Stroke—P2CCC · 48

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Immunoglobulin G4-Kappa, Anti-[Homo Sapiens Lgals3 (Galectin 3)], Humanized Monoclonal Antibody (Gamma4 Heavy Chain Humanized (1-442) [Vh (Homo Sapiens Ighv1-3*01 (88.7%) -(Ighd) -Ighj6*01 (93.3%), Cdr-Imgt [8.8.9] (26-33.51-58.97-105)) (1-116)-Homo Sapiens Ighg4*01, Ng4M(A) Ch2 L92, G4V5 H P10 (Ch1 (117-214), Hinge 1-12 S10>P (224)(215-226), Ch2 L92 (305) (227-336), Ch3 (337-441), Chs K2>Del (442)) (117-442)], (130-219')-Disulfide With Kappa Light Chain Humanized (1'-219') [V-Kappa(Homo Sapiens Igkv2D-29*02 (89.0%) -Igkj2*01(100%), Cdr-Imgt [11.3.9] (27-37.55-57.94-102)) (1'-112') -Homo Sapiens Igkc*01 (100%), Km3 A45.1(158), V101 (196) (113'-219')]; Dimer (222-222'':225-225'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Glycoform Alfa) in Alzheimer Disease. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/immunoglobulin-g4-kappa-anti-homo-sapiens-lgals3-galectin-3-humanized-monoclonal-antibody-gamma4-heavy-chain-humanized-1-442-vh-homo-sapiens-ighv1-301-887-ighd-ighj601-933-cdr-imgt-889-26-3351-5897-105-1-116-homo-sapiens-ighg401-ng4ma-ch2-l92-g4v5-h-p10-ch1-117-214-hinge-1-12-s10p-224215-226-ch2-l92-305-227-336-ch3-337-441-chs-k2del-442-117-442-130-219-disulfide-with-kappa-light-chain-humanized-1-219-v-kappahomo-sapiens-igkv2d-2902-890-igkj201100-cdr-imgt-1139-27-3755-5794-102-1-112-homo-sapiens-igkc01-100-km3-a451158-v101-196-113-219-dimer-222-222225-225-bisdisulfide-produced-in-chinese-hamster-ovary-cho-cells-glycoform-alfa-alzheimer-disease

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →